Investment Thesis
CapsoVision is a financially distressed medical device company with severe operational losses that far exceed revenues, negative free cash flow of -$15.3M, and deteriorating profitability. Despite healthy balance sheet liquidity metrics, the company is burning cash at an unsustainable rate with operating losses exceeding 180% of revenue, indicating fundamental business model challenges or failed commercialization efforts.
Strengths
- Solid current ratio of 5.19x and quick ratio of 4.50x indicating near-term liquidity is not an immediate concern
- Gross margin of 54.2% suggests products have reasonable unit economics when sold
- Minimal debt burden with 0.00x debt-to-equity ratio providing some financial flexibility
Risks
- Severe operating losses of -$18.1M on only $9.6M revenue demonstrates inability to control operating expenses or achieve necessary scale
- Negative free cash flow of -$15.3M annually is unsustainable and indicates ongoing cash burn that will deplete equity reserves
- Negative net margin of -186% and negative ROE of -87.7% reveal fundamental unprofitability with no clear path to breakeven
- Operating cash flow of -$15.2M mirrors free cash flow, indicating losses are actual cash outflows not accounting adjustments
Key Metrics to Watch
- Revenue growth rate and ability to reach scale that justifies current operating cost structure
- Operating expense reduction initiatives and timeline to operating break-even
- Quarterly cash burn rate and cash runway remaining before liquidity crisis
- Gross margin trends to confirm products remain economically viable
Financial Metrics
Revenue
9.6M
Net Income
-17.9M
EPS (Diluted)
$-1.05
Free Cash Flow
-15.3M
Total Assets
25.7M
Cash
N/A
Profitability Ratios
Gross Margin
54.2%
Operating Margin
-187.3%
Net Margin
-186.0%
ROE
-87.7%
ROA
-69.8%
FCF Margin
-158.4%
Balance Sheet & Liquidity
Current Ratio
5.19x
Quick Ratio
4.50x
Debt/Equity
0.00x
Debt/Assets
20.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-23T06:00:11.745014 |
Data as of: 2025-09-30 |
Powered by Claude AI